HSAQ vs. NSPR, CTCX, TMDIF, GBS, RVP, PETV, BTCY, IVF, DYNT, and IONM
Should you be buying Health Sciences Acquisitions Co. 2 stock or one of its competitors? The main competitors of Health Sciences Acquisitions Co. 2 include InspireMD (NSPR), Carmell (CTCX), Titan Medical (TMDIF), GBS (GBS), Retractable Technologies (RVP), PetVivo (PETV), Biotricity (BTCY), INVO Fertility (IVF), Dynatronics (DYNT), and Assure (IONM). These companies are all part of the "surgical & medical instruments" industry.
Health Sciences Acquisitions Co. 2 vs. Its Competitors
InspireMD (NYSE:NSPR) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.
44.8% of InspireMD shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 34.1% of InspireMD shares are held by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, InspireMD had 2 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 2 mentions for InspireMD and 0 mentions for Health Sciences Acquisitions Co. 2. InspireMD's average media sentiment score of 1.75 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that InspireMD is being referred to more favorably in the media.
InspireMD has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500.
InspireMD presently has a consensus target price of $4.50, indicating a potential upside of 87.11%. Given InspireMD's stronger consensus rating and higher probable upside, equities research analysts clearly believe InspireMD is more favorable than Health Sciences Acquisitions Co. 2.
Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to InspireMD's net margin of -413.96%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat InspireMD's return on equity.
Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than InspireMD.
Summary
InspireMD beats Health Sciences Acquisitions Co. 2 on 8 of the 13 factors compared between the two stocks.
Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSAQ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HSAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Health Sciences Acquisitions Co. 2 Competitors List
Related Companies and Tools
This page (NASDAQ:HSAQ) was last updated on 9/9/2025 by MarketBeat.com Staff
